Bankruptcy Alert Urgent sales focus should account for the company’s bankruptcy filing in June 2026, signaling a redirected procurement process, a potential need for liquidation of assets, and a shift in partnerships or customer contracts within hospital systems and liver disease/CHF/cancer care networks.

Clinical Focus Target healthcare providers treating fluid overload in liver disease, heart failure, and cancer. Highlight alfapump and DSR technologies as differentiated solutions that may reduce hospitalizations and inpatient costs, aligning with payer and hospital efficiency goals.

Funding runway Note the recent financing infusion extending cash runway, suggesting appetite from investors and potential for strategic partnerships, licensing, or continuation of clinical programs—scouts for co-development, distribution, or joint ventures.

European footprint Leverage the Ghent headquarters and European listing to prioritize EMEA market entry strategies, regulatory navigation, and potential local distributors or service partners to accelerate adoption in major European healthcare systems.

Engagement channels Recent conference attendance and sponsorship activity indicate active engagement with surgical and liver disease communities; leverage event follow-ups and digital channels to re-engage prospects, demonstrate outcomes data, and drive trial or pilot opportunities.